Team

Opportunity Pharma OpenEye

Opportunity Pharma and OpenEye, Cadence Molecular Sciences join forces

Opportunity Pharma and OpenEye, Cadence Molecular Sciences, have signed an agreement whereby Opportunity Pharma will utilise OpenEye’s software to power the development of its proprietary AI virtual expert for drug discovery investors. OpenEye, Cadence Molecular Sciences, an industry leader in computational molecular design, has pioneered physics-based approaches and the cloud-native Orion® molecular modelling software platform […]

Opportunity Pharma and OpenEye, Cadence Molecular Sciences join forces Read More »

The Grand Challenge

Inventing a new medicine is very difficult and at 95%, the rate of failure is staggeringly high. We shouldn’t be surprised at this. Human biology is very complex and still far from being understood, especially in disease, when processes fail. Even when scientists begin to unravel the causes of disease, finding a drug with just

The Grand Challenge Read More »